A Single-Blind Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Repeat Doses of GSK249320 in Patients With Ischaemic Stroke.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Refanezumab (Primary)
- Indications Stroke
- Focus Adverse reactions; Biomarker
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 25 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Apr 2010 Additional trial location [Germany] identified as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History